AtheroGenics, Inc. (AtheroGenics), incorporated in 1993, is a research-based pharmaceutical company that focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including coronary heart disease (CHD), organ transplant rejection, rheumatoid arthritis and asthma. The Company has developed the v-protectant technology platform to discover drugs to treat these types of diseases. Based on its v-protectant platform, AtheroGenics has two drug development programs in clinical trials and is pursuing a number of other preclinical programs. AGI-1067 is its v-protectant candidate, which is in advanced clinical development. AGI-1067 is designed to benefit patients with CHD, which is atherosclerosis of the blood vessels of the heart. AGI-1096, its second v-protectant candidate, is an antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection. AGI-1067 AGI-1067 is designed to address atherosclerosis (CHD), a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls. The anti-inflammatory mechanism of AGI-1067 represents a novel, direct therapeutic approach that may be suitable as a chronic treatment for all patients with CHD, including those without traditional risk factors. During the year ended December 31, 2004, AtheroGenics completed a Phase IIb clinical trial called CART-2, a 465-patient study that examined the effect of 12 months of AGI-1067 therapy on atherosclerosis and post-angioplasty restenosis, which is the re-narrowing of the arteries following angioplasty. The primary endpoint of the trial was a change in coronary atherosclerosis, measured as total plaque volume after a 12-month treatment period compared to baseline values. Combined results of the final analysis from the two laboratories, which were based on an evaluation of intravascular ultrasounds from approximately 230 patients in the study, indicate that AGI-1067 reduced plaque volume by an average of 2.3%, which was statistically significant. Based on the results of an end of Phase II meeting with the Unite States Food and Drug Administration (FDA), a pivotal Phase III clinical trial protocol was developed to evaluate AGI-1067 for the treatment of atherosclerosis. The Phase III protocol has received a Special Protocol Assessment from the FDA during the year ended December 31, 2003. A Special Protocol Assessment is written confirmation from the FDA that the protocol is adequately designed to support a New Drug Application (NDA) for the drug in the specified treatment area. In 2003, AtheroGenics initiated the pivotal Phase III trial Aggressive Reduction of Inflammation Stops Events (ARISE), which is being conducted in cardiac centers in the United States, Canada, the United Kingdom and South Africa. ARISE will evaluate the impact of AGI-1067 on important outcome measures, such as death due to coronary disease, myocardial infarction, stroke, coronary re-vascularization and unstable angina in patients who have CHD. The study will assess the incremental benefits of AGI-1067 versus the current standard of care therapies in this patient population. In February 2005, the FDA approved a proposed amendment to the ARISE Phase III clinical trial protocol. The changes to the ARISE clinical trial protocol were intended to enhance the trial, as well as to accelerate its pace without affecting the Special Protocol Assessment with the FDA. The changes approved by the FDA included a plan to increase the number of patients in the study to 6,000, eliminate the minimum 12-month, follow-up period for patients and decrease the minimum number of primary events to 990. Patient enrollment has been completed with a total of 6,127 patients in the study. The ARISE trial is expected to be completed in 2006 to be followed by the filing of an NDA with the FDA in 2007. In December 2005, AtheroGenics announced

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/24/2025 11:07 PDT] AGIX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.